FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPES

代谢型谷氨酸受体亚型的功能

基本信息

  • 批准号:
    6393608
  • 负责人:
  • 金额:
    $ 34.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1993
  • 资助国家:
    美国
  • 起止时间:
    1993-08-01 至 2004-07-31
  • 项目状态:
    已结题

项目摘要

The hippocampus plays an important role in a number of normal physiological processes and in a variety of pathological conditions, including Alzheimer's disease and temporal lobe epilepsy. Development of a complete understanding of the molecular and cellular mechanisms involved in regulation of hippocampal function could lead to new strategies for treatment of these disorders. Until recently, it was thought that all of the actions of glutamate, the major excitatory neurotransmitter in the hippocampus, were mediated by activation of ligand-gated cation channels. However, it is now clear that glutamate also activates metabotropic glutamate receptors (mGluRs), that are coupled to effector systems through GTP binding proteins. mGluRs play a number of important roles in regulating cell excitability and synaptic transmission in the hippocampus. A complete understanding of both normal and pathological hippocampal function will require a detailed understanding of the roles of mGluRs in modulating hippocampal physiology and the molecular mechanisms involved in regulating signaling by members of this important receptor family. Eight m(GluR subtypes (mGluR1 - mGluR8) have been identified by molecular cloning. In the hippocampus, evidence suggests that m(GluR2, mGluR7 and mGluR8 are all localized on presynaptic glutamatergic nerve terminals where they may serve to inhibit glutamate release. However, the postulated roles of mGluR7 and mGluR8 in regulating transmission at specific hippocampal synapses have not been definitively established. We recently reported that mGluR- mediated regulation of glutamate release can be inhibited by activation of protein kinase C (PKC). However, at present, the mechanism by which PKC inhibits signaling by presynaptic mGluRs is not known. A series of studies is proposed in which a combination of anatomical, pharmacological, and genetic approaches will be used to rigorously test the hypothesis that mGluR7 and m(GluR8 serve as presynaptic receptors at two major hippocampal synapses. We will then employ biochemical, electrophysiological, and molecular approaches to rigorously test the hypothesis that activation of PKC inhibits the function of presynaptic mGluRs by directly phosphorylating the receptors and inhibiting receptor coupling to GTP binding proteins. These studies could lead to a fundamental advance in our understanding of the mechanisms involved in regulation hippocampal function and could have important implications regarding novel approaches to treatment of disorders involving pathological changes in the hippocampus.
海马体在许多正常生理过程和各种病理状况(包括阿尔茨海默病和颞叶癫痫)中发挥着重要作用。 对海马功能调节所涉及的分子和细胞机制的全面了解可能会导致治疗这些疾病的新策略。直到最近,人们还认为谷氨酸(海马体中主要的兴奋性神经递质)的所有作用都是由配体门控阳离子通道的激活介导的。然而,现在很清楚,谷氨酸还可以激活代谢型谷氨酸受体 (mGluR),该受体通过 GTP 结合蛋白与效应系统偶联。 mGluR 在调节海马细胞兴奋性和突触传递方面发挥着许多重要作用。 要全面了解正常和病理性海马功能,需要详细了解 mGluR 在调节海马生理学中的作用以及参与调节这一重要受体家族成员信号传导的分子机制。已通过分子克隆鉴定出八种 m(GluR1 - mGluR8) 亚型。在海马中,有证据表明 m(GluR2、mGluR7 和 mGluR8 均位于突触前谷氨酸能神经末梢,在那里它们可能起到抑制谷氨酸释放的作用。然而,mGluR7 和 mGluR8 的假定作用 调节特定海马突触的传递尚未明确确定。 我们最近报道,mGluR 介导的谷氨酸释放调节可以通过蛋白激酶 C (PKC) 的激活来抑制。然而,目前,PKC 抑制突触前 mGluR 信号传导的机制尚不清楚。提出了一系列研究,其中结合了解剖学、药理学和 遗传学方法将用于严格检验 mGluR7 和 m(GluR8 在两个主要海马突触中作为突触前受体的假设。然后,我们将采用生化、电生理学和分子方法来严格检验 PKC 的激活通过直接磷酸化受体和抑制受体来抑制突触前 mGluR 功能的假设 与 GTP 结合蛋白偶联。这些研究可能使我们对海马功能调节机制的理解取得根本性进展,并且可能对治疗涉及海马病理变化的疾病的新方法产生重要影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

P Jeffrey Conn其他文献

Promise of mGluR2/3 activators in psychiatry
mGluR2/3 激活剂在精神病学中的前景
  • DOI:
    10.1038/npp.2008.156
  • 发表时间:
    2008-12-12
  • 期刊:
  • 影响因子:
    7.100
  • 作者:
    P Jeffrey Conn;Carrie K Jones
  • 通讯作者:
    Carrie K Jones
Ethanol-Induced Adaptations to Inhibitory Microcircuits in the Mouse Prefrontal Cortex
  • DOI:
    10.1016/j.biopsych.2021.02.313
  • 发表时间:
    2021-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Max Joffe;Anthony Ferranti;Danny Winder;P Jeffrey Conn
  • 通讯作者:
    P Jeffrey Conn
Pharmacological Treatments for Autism Spectrum Disorder: Will Emerging Approaches Yield New Treatments?
自闭症谱系障碍的药物治疗:新兴方法会产生新的治疗方法吗?
  • DOI:
    10.1038/npp.2015.259
  • 发表时间:
    2015-12-10
  • 期刊:
  • 影响因子:
    7.100
  • 作者:
    Rocco G Gogliotti;P Jeffrey Conn
  • 通讯作者:
    P Jeffrey Conn

P Jeffrey Conn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('P Jeffrey Conn', 18)}}的其他基金

Discovery of mGlu receptor PAMs for treatment of schizophrenia
发现 mGlu 受体 PAM 用于治疗精神分裂症
  • 批准号:
    10531546
  • 财政年份:
    2019
  • 资助金额:
    $ 34.22万
  • 项目类别:
Discovery of mGlu receptor PAMs for treatment of schizophrenia
发现 mGlu 受体 PAM 用于治疗精神分裂症
  • 批准号:
    10305625
  • 财政年份:
    2019
  • 资助金额:
    $ 34.22万
  • 项目类别:
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics
新型 mGlu5 负变构调节剂作为一流的非成瘾镇痛疗法
  • 批准号:
    10450295
  • 财政年份:
    2019
  • 资助金额:
    $ 34.22万
  • 项目类别:
Discovery of mGlu receptor PAMs for treatment of schizophrenia
发现 mGlu 受体 PAM 用于治疗精神分裂症
  • 批准号:
    10063834
  • 财政年份:
    2019
  • 资助金额:
    $ 34.22万
  • 项目类别:
Novel mGlu5 Negative Allosteric Modulators as First-in-Class Non-Addictive Analgesic Therapeutics
新型 mGlu5 负变构调节剂作为一流的非成瘾性镇痛治疗药物
  • 批准号:
    10477066
  • 财政年份:
    2019
  • 资助金额:
    $ 34.22万
  • 项目类别:
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics
新型 mGlu5 负变构调节剂作为一流的非成瘾镇痛疗法
  • 批准号:
    10581793
  • 财政年份:
    2019
  • 资助金额:
    $ 34.22万
  • 项目类别:
Development of an M1 PAM experimental therapeutic for schizophrenia
开发治疗精神分裂症的 M1 PAM 实验疗法
  • 批准号:
    9140071
  • 财政年份:
    2015
  • 资助金额:
    $ 34.22万
  • 项目类别:
Development of mGIuR5 NAMS for Treatment of Major Depression
mGIuR5 NAMS 的开发用于治疗重度抑郁症
  • 批准号:
    8434427
  • 财政年份:
    2013
  • 资助金额:
    $ 34.22万
  • 项目类别:
Development of mGIuR5 NAMS for Treatment of Major Depression
用于治疗重度抑郁症的 mGIuR5 NAMS 的开发
  • 批准号:
    8603872
  • 财政年份:
    2013
  • 资助金额:
    $ 34.22万
  • 项目类别:
Discovery and Optimization of Selective Negative Allosteric Modulators of mGluR3
mGluR3 选择性负变构调节剂的发现和优化
  • 批准号:
    8726488
  • 财政年份:
    2012
  • 资助金额:
    $ 34.22万
  • 项目类别:

相似海外基金

Impact of metabotropic glutamate receptor heteromerization on signaling and pharmacology
代谢型谷氨酸受体异聚化对信号传导和药理学的影响
  • 批准号:
    10637938
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
Subtype-Selective Metabotropic Glutamate Receptor PET Ligands
亚型选择性代谢型谷氨酸受体 PET 配体
  • 批准号:
    10576674
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
Structural and metabotropic signaling mechanisms of the delta2 glutamate receptor
δ2 谷氨酸受体的结构和代谢信号传导机制
  • 批准号:
    23K05967
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Metabotropic glutamate receptor signalling: a new drug target for longevity.
代谢型谷氨酸受体信号传导:长寿的新药物靶点。
  • 批准号:
    BB/T001488/2
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
    Research Grant
Molecular basis of glutamate receptor trafficking in neuronal plasticity
神经元可塑性中谷氨酸受体运输的分子基础
  • 批准号:
    FT220100485
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
    ARC Future Fellowships
Analysis of modulation of the metabotropic glutamate receptor type 5 in a novel heritable model of drug abuse vulnerability
药物滥用易感性新型遗传模型中 5 型代谢型谷氨酸受体的调节分析
  • 批准号:
    10754809
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
Defining native glutamate receptor diversity
定义天然谷氨酸受体多样性
  • 批准号:
    10511509
  • 财政年份:
    2022
  • 资助金额:
    $ 34.22万
  • 项目类别:
Regulation of activity-induced glutamate receptor trafficking in neurons
神经元中活动诱导的谷氨酸受体运输的调节
  • 批准号:
    DP220101645
  • 财政年份:
    2022
  • 资助金额:
    $ 34.22万
  • 项目类别:
    Discovery Projects
Structure and Function of native kainate-type ionotropic glutamate receptor complexes
天然红藻氨酸型离子型谷氨酸受体复合物的结构和功能
  • 批准号:
    10696091
  • 财政年份:
    2022
  • 资助金额:
    $ 34.22万
  • 项目类别:
PET imaging of ionotropic glutamate receptor signaling in Alzheimer's disease
阿尔茨海默病中离子型谷氨酸受体信号传导的 PET 成像
  • 批准号:
    10574694
  • 财政年份:
    2022
  • 资助金额:
    $ 34.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了